SINGULAIR (montelukast sodium) by Merck & Co. is leukotriene receptor antagonists [moa]. First approved in 2002.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
SINGULAIR (montelukast sodium) is an oral leukotriene receptor antagonist approved in 2002 for asthma and allergic rhinitis. It works by blocking leukotriene receptors on airway and inflammatory cells, reducing inflammation and bronchoconstriction. The drug is available as a granule formulation for convenient dosing across age groups.
Mature product approaching loss of exclusivity with limited Part D utilization; commercial team focus likely shifting to generic transition and retention strategy rather than growth.
Leukotriene Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Worked on SINGULAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SINGULAIR in 2024 is a career consolidation role rather than a growth opportunity; the product offers limited learning in launch or expansion dynamics. Professionals should view this assignment as a stepping stone to emerging assets or leverage the reimbursement and competitive analysis experience to transition into LOE/generic strategy roles.